RU98119312A - APPLICATION OF DERIVATIVES OF RAPAMYCIN IN VASOPATHIES AND XENOTRANSPLANTATION - Google Patents

Claims (10)

1. The use of the compounds of formula I

where X denotes (H, H) or O;
Y represents (H, OH) or O;
R ¹ and R ² are independently selected from the group consisting of H, alkyl, arylalkyl, hydroxyalkyl, digidroksialkil, gidroksialkoksikarbonilalkil, gidroksialkilarilalkil, digidroksialkilarilalkil, acyloxyalkyl, aminoalkyl, alkylaminoalkyl, alkoxycarbonylaminoalkyl, acylaminoalkyl, arilsulfonamidoalkil, allyl, digidroksialkilallil, dioksolanilallil, dialkildioksolanilalkil, di (alkoxycarbonyl) triazolylalkyl and hydroxyalkoxyalkyl, where “alk-” or “alkyl” means branched or linear C ₁ -C ₆ alkyl, “aryl” means phenyl or tolyl and "acyl" means a radical derived from a carboxylic acid;
R ⁴ is methyl or R ⁴ and R ¹ together form a C ₂ -C ₆ alkyl;
provided that R ¹ and R ² together cannot designate H, and hydroxyalkoxyalkyl does not mean hydroxyalkoxymethyl, in the manufacture of a pharmaceutical composition intended to prevent or treat the proliferation and thickening of a new inner shell.  2. The use of the compounds of formula I according to claim 1 in the manufacture of a pharmaceutical composition intended to prevent or reduce the symptoms of chronic rejection of a transplanted organ or tissue in a recipient.  3. The use of the compound of the formula I according to claim 1 in the manufacture of a pharmaceutical composition for preventing or treating restenosis and / or occlusions of a vessel resulting from damage to the vessel.  4. The use of the compound of formula I according to claim 1 in the manufacture of a pharmaceutical composition intended to prevent or reduce acute or chronic rejection in a recipient of an organ or tissue transplant, which is a xenograft.  5. The use of a compound of formula I in accordance with claim 1 for preventing or treating proliferation and thickening of the inner lining, restenosis and / or occlusions of a vessel resulting from damage to the vessel, or to prevent or reduce symptoms of chronic rejection of a transplanted organ or tissue in a recipient, acute or chronic rejection in the recipient of an organ or tissue transplant that is a xenograft.  6. Pharmaceutical composition intended to prevent or treat the proliferation and thickening of the new inner lining, restenosis and / or occlusions of vessels resulting from vessel damage, or to prevent or reduce the symptoms of chronic rejection of a transplanted organ or tissue in a recipient, acute or chronic rejection in a recipient a graft of an organ or tissue representing a xenograft comprising a compound of formula I in accordance with claim 1, together with one or more pharmaceutics Eski acceptable diluents or carriers.  7. A method of preventing or treating proliferation and thickening of the new inner lining, restenosis and / or occlusions of the vessel resulting from damage to the vessel, including the stage of administering to the recipient a therapeutically effective amount of the compound of formula I in claim 1.  8. A method of preventing or reducing the symptoms of chronic rejection of a transplanted organ or tissue in a recipient, acute or chronic rejection in a recipient of an organ or tissue transplant, which is a xenograft, comprising the step of administering to the recipient a therapeutically effective amount of the compound of formula I in claim 1.  9. The use according to any one of paragraphs. 1-5, where the compound of formula I is a 40-O- (2-hydroxy) ethyl rapamycin.  10. The pharmaceutical composition of claim 6, wherein the compound of formula I is 40-O- (2-hydroxy) ethyl rapamycin.